RS59678B1 - Derivati 8-hidroksi-hinolina - Google Patents
Derivati 8-hidroksi-hinolinaInfo
- Publication number
- RS59678B1 RS59678B1 RS20191622A RSP20191622A RS59678B1 RS 59678 B1 RS59678 B1 RS 59678B1 RS 20191622 A RS20191622 A RS 20191622A RS P20191622 A RSP20191622 A RS P20191622A RS 59678 B1 RS59678 B1 RS 59678B1
- Authority
- RS
- Serbia
- Prior art keywords
- group
- groups
- methyl
- branched
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1000243A HUP1000243A2 (en) | 2010-05-06 | 2010-05-06 | 8-hidroxy-quinoline derivatives |
| EP11752335.7A EP2566849B1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
| PCT/HU2011/000043 WO2011148208A1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59678B1 true RS59678B1 (sr) | 2020-01-31 |
Family
ID=89989711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20191622A RS59678B1 (sr) | 2010-05-06 | 2011-05-06 | Derivati 8-hidroksi-hinolina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8871937B2 (enExample) |
| EP (1) | EP2566849B1 (enExample) |
| JP (1) | JP5812541B2 (enExample) |
| KR (1) | KR101837974B1 (enExample) |
| CN (1) | CN102985407B (enExample) |
| AU (1) | AU2011256989B2 (enExample) |
| CA (1) | CA2798419C (enExample) |
| CY (1) | CY1122426T1 (enExample) |
| DK (1) | DK2566849T3 (enExample) |
| EA (1) | EA021026B1 (enExample) |
| ES (1) | ES2761832T3 (enExample) |
| HR (1) | HRP20192278T1 (enExample) |
| HU (2) | HUP1000243A2 (enExample) |
| MX (1) | MX337999B (enExample) |
| NZ (1) | NZ603967A (enExample) |
| PL (1) | PL2566849T3 (enExample) |
| PT (1) | PT2566849T (enExample) |
| RS (1) | RS59678B1 (enExample) |
| SI (1) | SI2566849T1 (enExample) |
| SM (1) | SMT201900710T1 (enExample) |
| WO (1) | WO2011148208A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1500098A2 (hu) * | 2015-03-09 | 2016-09-28 | Avidin Kft | 8-hidroxikinolin származékok új enantiomerjei és szintézisük |
| WO2017066245A1 (en) * | 2015-10-12 | 2017-04-20 | Health Research, Inc. | Methods for inducing apoptosis in cancer cells |
| CN105367553A (zh) * | 2015-12-04 | 2016-03-02 | 广东工业大学 | 一种他克林-8-羟（胺）基喹啉衍生物及其应用 |
| HUP1600234A2 (en) | 2016-04-05 | 2017-12-28 | Mta Termeszettudomanyi Kutatokoezpont | Mdr-reversing 8-hydroxy-quinoline derivatives |
| WO2024073624A2 (en) * | 2022-09-28 | 2024-04-04 | The Research Foundation For The State University Of New York | Antiproliferative betti bases and prodrugs thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999015179A1 (en) | 1997-09-25 | 1999-04-01 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| AU2474399A (en) | 1998-01-26 | 1999-08-09 | Mitokor | Mitochondria protecting agents for treating mitochondria associated diseases |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| DE60040397D1 (de) | 1999-08-27 | 2008-11-13 | Cytovia Inc | Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung |
| US6890896B1 (en) | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| GB0011095D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | astrin and cholecystokinin receptor ligands (III) |
| US6521617B2 (en) | 2000-10-13 | 2003-02-18 | The Johns Hopkins University | Treatment of apoptotic cell death |
| WO2002048092A2 (en) | 2000-12-15 | 2002-06-20 | Mitokor | Compounds for altering mitochondrial function and cellular responses |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| EP1414948B1 (en) | 2001-07-10 | 2009-09-16 | Biogen Idec Inc. | Inhibition of apoptosis process and improvement of cell performance |
| DE10144153A1 (de) | 2001-09-07 | 2003-03-27 | Newfrey Llc | Halteclip mit versetzten Rastfingern |
| EA200401070A1 (ru) | 2002-02-13 | 2005-02-24 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Способы лечения сосудистых заболеваний |
| WO2005072295A2 (en) | 2004-01-23 | 2005-08-11 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| AU2004258801A1 (en) | 2003-02-28 | 2005-02-03 | Inotek Pharmaceuticals Corporation | Tetracyclic Benzamide Derivatives and methods of use thereof |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| ES2396334T3 (es) | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7462724B2 (en) | 2005-11-15 | 2008-12-09 | Abbott Laboratories | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors |
| US7528174B2 (en) | 2006-01-06 | 2009-05-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Selective targeting agents for mitochondria |
| CA2658793A1 (en) * | 2006-07-25 | 2008-02-07 | Daniel Dumas | Quinoline derivatives |
| EP2139460A4 (en) * | 2007-03-20 | 2011-09-07 | Univ Brandeis | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES |
| US8183236B2 (en) * | 2007-04-12 | 2012-05-22 | University Of Southern California | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics |
| CA2687187A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| US10301265B2 (en) * | 2008-05-28 | 2019-05-28 | Virginia I. Roxas-Duncan | Small molecule inhibitors of botulinum neurotoxins |
| EP2521551A4 (en) * | 2010-01-06 | 2013-08-21 | Errico Joseph P | METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT |
| US8658170B2 (en) * | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
-
2010
- 2010-05-06 HU HU1000243A patent/HUP1000243A2/hu unknown
-
2011
- 2011-05-06 NZ NZ603967A patent/NZ603967A/en not_active IP Right Cessation
- 2011-05-06 DK DK11752335.7T patent/DK2566849T3/da active
- 2011-05-06 RS RS20191622A patent/RS59678B1/sr unknown
- 2011-05-06 AU AU2011256989A patent/AU2011256989B2/en not_active Ceased
- 2011-05-06 SM SM20190710T patent/SMT201900710T1/it unknown
- 2011-05-06 WO PCT/HU2011/000043 patent/WO2011148208A1/en not_active Ceased
- 2011-05-06 MX MX2012012883A patent/MX337999B/es active IP Right Grant
- 2011-05-06 EP EP11752335.7A patent/EP2566849B1/en active Active
- 2011-05-06 EA EA201270787A patent/EA021026B1/ru unknown
- 2011-05-06 HR HRP20192278TT patent/HRP20192278T1/hr unknown
- 2011-05-06 CA CA2798419A patent/CA2798419C/en active Active
- 2011-05-06 PL PL11752335T patent/PL2566849T3/pl unknown
- 2011-05-06 ES ES11752335T patent/ES2761832T3/es active Active
- 2011-05-06 CN CN201180033524.5A patent/CN102985407B/zh active Active
- 2011-05-06 KR KR1020127030702A patent/KR101837974B1/ko active Active
- 2011-05-06 JP JP2013508559A patent/JP5812541B2/ja active Active
- 2011-05-06 US US13/696,541 patent/US8871937B2/en active Active
- 2011-05-06 HU HUE11752335A patent/HUE050886T2/hu unknown
- 2011-05-06 SI SI201131826T patent/SI2566849T1/sl unknown
- 2011-05-06 PT PT117523357T patent/PT2566849T/pt unknown
-
2019
- 2019-12-17 CY CY20191101327T patent/CY1122426T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20192278T1 (hr) | 2020-03-06 |
| HU1000243D0 (en) | 2010-06-28 |
| CN102985407A (zh) | 2013-03-20 |
| US20130131096A1 (en) | 2013-05-23 |
| HUP1000243A2 (en) | 2012-01-30 |
| US8871937B2 (en) | 2014-10-28 |
| AU2011256989B2 (en) | 2014-08-21 |
| AU2011256989A1 (en) | 2013-01-10 |
| NZ603967A (en) | 2014-06-27 |
| JP5812541B2 (ja) | 2015-11-17 |
| SMT201900710T1 (it) | 2020-01-14 |
| DK2566849T3 (da) | 2020-01-02 |
| MX337999B (es) | 2016-03-30 |
| EA201270787A1 (ru) | 2013-04-30 |
| HUE050886T2 (hu) | 2021-01-28 |
| CA2798419A1 (en) | 2011-12-01 |
| WO2011148208A1 (en) | 2011-12-01 |
| PT2566849T (pt) | 2020-01-06 |
| ES2761832T3 (es) | 2020-05-21 |
| KR20130029772A (ko) | 2013-03-25 |
| EA021026B1 (ru) | 2015-03-31 |
| PL2566849T3 (pl) | 2020-03-31 |
| KR101837974B1 (ko) | 2018-03-13 |
| SI2566849T1 (sl) | 2020-02-28 |
| EP2566849B1 (en) | 2019-09-18 |
| CY1122426T1 (el) | 2021-01-27 |
| JP2013525473A (ja) | 2013-06-20 |
| CA2798419C (en) | 2021-01-05 |
| EP2566849A1 (en) | 2013-03-13 |
| MX2012012883A (es) | 2013-03-20 |
| CN102985407B (zh) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thakkar et al. | Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities | |
| US10464925B2 (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
| US8513433B2 (en) | Small molecule inhibitors of PARP activity | |
| BG65047B1 (bg) | Заместени бензимидазоли и тяхното използване катоparp инхибитори | |
| HUE029370T2 (hu) | Rákellenes aktivitású vegyületek | |
| KR102333863B1 (ko) | 신규한 피라졸 유도체 | |
| RS59678B1 (sr) | Derivati 8-hidroksi-hinolina | |
| WO2016148114A1 (ja) | 酸化ストレス誘導神経細胞死抑制化合物 | |
| KR20160003196A (ko) | ＂니코틴아미드 포스포리보실트랜스퍼라제의 억제제, 조성물, 제품 및 그의 용도＂ | |
| Qiu et al. | Discovery of novel harmine derivatives as GSK‐3β/DYRK1A dual inhibitors for Alzheimer's disease treatment | |
| CN107857760A (zh) | 鞘氨醇‑1‑磷酸受体调节剂及其应用 | |
| JP4794445B2 (ja) | キノリンカリウムチャネル阻害剤 | |
| CN116891463A (zh) | 作为at2r激动剂的杂环化合物 | |
| AU2017341020B2 (en) | Urea derivative | |
| CA3093551A1 (en) | Compounds for treatment of cardiac arrhythmias and heart failure | |
| WO2009017874A9 (en) | Novel curcumin derivatives and their pharmaceutical uses thereof | |
| US9381260B2 (en) | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | |
| JP2001302669A (ja) | 三環性フタラジノン誘導体 | |
| CN112823006B (zh) | 用作神经保护剂的醌还原酶2抑制剂 | |
| CN113956249B (zh) | 脑靶向AChE抑制剂前药及其制备方法与应用 | |
| KR20080053950A (ko) | 오르토 치환 아닐린 유도체 및 항산화약 | |
| CN107383002A (zh) | 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途 | |
| CN120051457A (zh) | 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途 |